This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Urinary Cytokines in Patients With Overactive Bladder (OAB)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2009 by Cleveland Clinic Florida.
Recruitment status was:  Active, not recruiting
Astellas Pharma US, Inc.
Information provided by:
Cleveland Clinic Florida Identifier:
First received: March 23, 2009
Last updated: NA
Last verified: March 2009
History: No changes posted
Overactive bladder (OAB) is a widespread condition characterized by urgency, urge incontinence, nocturia and excessive urinary frequency, affecting millions of people worldwide.(1) In two epidemiological studies, OAB was found in about 17% of American and European populations.(2)(3). This accounts for an estimated 33 million patients suffering from OAB in the USA. The disorder constitutes a psychological stress that impacts the patient's social life.

Overactive Bladder Urinary Tract Infection

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Identification of Urinary Cytokines in Patients With Overactive Bladder (OAB)

Resource links provided by NLM:

Further study details as provided by Cleveland Clinic Florida:

Enrollment: 56
Study Start Date: March 2007
Estimated Study Completion Date: June 2009
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Overactive Bladder Patients
Urinary Tract Infection

  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Twenty healthy women (control), 20 women suffering from overactive bladder and other 20 women suffering from UTI will be selected for the study. Each control will be age matched within +/- 5 years to patients.

Inclusion Criteria:

  • Group I (OAB patients)

    1. Women with OAB, ≥18 years and premenopausal non-menstruating, not on any anticholinergic for at least two weeks before enrollment in the study.
    2. Significant urgency,i.e., having moderate or severe urgency score.
    3. Having a score > 8 on the OAB-V8 questionnaire.
    4. Urinary frequency of more than 8/day, with urgency of urination, with or without urge incontinence.
    5. Negative screening urinalysis one month after documented UTI.
  • Group II (Control)

    1. Age-matched normal volunteers (≥18 years and premenopausal non-menstruating)
    2. No Urgency.
    3. OAB-8 score < 8.
    4. No UTI.
  • Group III (UTl)

    1. Age-matched
    2. ≥18 years and premenopausal non-menstruating women with culture proven UTI.

Exclusion Criteria:

  1. Treatable genitourinary conditions that could cause incontinence
  2. Hematuria
  3. Obstructive uropathy
  4. Patients diagnosed with vaginitis
  5. History of urothelial carcinoma
  6. Urinary tract infection (except group III)
  7. Pelvic radiation.
  8. Neurogenic bladder.
  9. Renal pathology.
  10. Stress urinary incontinence.
  11. Medications.
  12. Recent history of Botox injection in the bladder (Within the last year).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00868621

United States, Florida
Cleveland Clinic Florida
Weston, Florida, United States, 33331
Sponsors and Collaborators
Cleveland Clinic Florida
Astellas Pharma US, Inc.
Principal Investigator: Gamal Ghoniem, MD Cleveland Clinic Florida
  More Information


Responsible Party: Astellas Pharma, US Inc, Cleveland Clinic Florida Identifier: NCT00868621     History of Changes
Other Study ID Numbers: IRB 8848
Study First Received: March 23, 2009
Last Updated: March 23, 2009

Additional relevant MeSH terms:
Urinary Bladder, Overactive
Urinary Tract Infections
Urinary Bladder Diseases
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations
Signs and Symptoms
Infection processed this record on July 26, 2017